Free Trial
NASDAQ:CV

CapsoVision (CV) Stock Price, News & Analysis

CapsoVision logo
$6.73 -0.10 (-1.46%)
As of 12:49 PM Eastern
This is a fair market value price provided by Massive. Learn more.

About CapsoVision Stock (NASDAQ:CV)

Advanced

Key Stats

Today's Range
$6.78
▼
$7.03
50-Day Range
$5.82
▼
$7.06
52-Week Range
$4.50
▼
$15.37
Volume
23,789 shs
Average Volume
235,815 shs
Market Capitalization
$336.82 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.50
Consensus Rating
Hold

Company Overview

CapsoVision, Inc. is a medical technology company focused on developing and commercializing diagnostic solutions for gastrointestinal diseases. The company’s primary product is the CapsoCam Plus capsule endoscope, an ingestible camera that captures images of the gastrointestinal tract as it passes through the digestive system.

CapsoCam Plus is designed to provide panoramic imaging, including a 360-degree view, to help physicians examine areas of the small bowel that can be difficult to assess using conventional endoscopy. CapsoVision also offers related software and cloud-based tools intended to support the retrieval, processing, review and interpretation of capsule endoscopy images.

Based in the United States, CapsoVision serves healthcare providers through domestic and international markets. Its products are intended for use in gastrointestinal diagnosis and complement other endoscopic procedures used by gastroenterologists and medical professionals.

AI Generated. May Contain Errors.

CapsoVision Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
69th Percentile Overall Score

CV MarketRank™: 
3.465753424655 of 5 stars

CapsoVision scored higher than 69% of companies evaluated by MarketBeat, and ranked 357th out of 894 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    CapsoVision has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on no strong buy ratings, 2 buy ratings, 1 hold rating, and 1 sell rating.

  • Upside Potential

    CapsoVision has a consensus price target of $9.50, representing about 38.9% upside from its current price of $6.84.

  • Amount of Analyst Coverage

    CapsoVision has only been the subject of 4 research reports in the past 90 days.

  • Read more about CapsoVision's stock forecast and price target.
  • Earnings Growth

    Earnings for CapsoVision are expected to grow in the coming year, from ($0.56) to ($0.45) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of CapsoVision is -14.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of CapsoVision is -14.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    CapsoVision has a P/B Ratio of 24.43. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    4.46% of the float of CapsoVision has been sold short.
  • Short Interest Ratio / Days to Cover

    CapsoVision has a short interest ratio ("days to cover") of 21.23, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in CapsoVision has recently increased by 3.68%, indicating that investor sentiment is decreasing.
  • News Sentiment

    CapsoVision has a news sentiment score of 0.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for CapsoVision this week, compared to 2 articles on an average week.
  • Search Interest

    3 people have searched for CV on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.
  • Cluster Insider Buying

    2 insiders have purchased shares of CapsoVision in the last three months. Multiple insiders buying is a strong bullish signal.

  • Net Insider Buying

    Over the last three months, insiders have purchased a net $14,999,995.00 in company stock, which represents 4.3818% of the company's market cap.

  • Insider Buying vs. Insider Selling

    In the past three months, CapsoVision insiders have bought more of their company's stock than they have sold. Specifically, they have bought $14,999,995.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    2.30% of the stock of CapsoVision is held by insiders.

  • Percentage Held by Institutions

    CapsoVision has minimal institutional ownership at this time.

  • Read more about CapsoVision's insider trading history.
Receive CV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CapsoVision and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

CV Stock News Headlines

Elon Musk’s One Stock Retirement Plan
Stanley Druckenmiller once said you don't get rich diversifying into 50 mediocre assets - you get rich finding two or three asymmetric home runs. Analyst Jeff Brown says he has identified a new one, a single stock he calls Elon Musk's One Stock Retirement Plan.tc pixel
CapsoVision Wins FDA Clearance For AI Highlights Tool
CapsoVision Wins FDA Clearance for AI Endoscopy Tool
See More Headlines

CV Stock Analysis - Frequently Asked Questions

CapsoVision's stock was trading at $10.69 at the start of the year. Since then, CV stock has decreased by 36.0% and is now trading at $6.84.

CapsoVision, Inc. (NASDAQ:CV) posted its quarterly earnings data on Thursday, August, 13th. The company reported ($0.15) EPS for the quarter. The business earned $3.64 million during the quarter. CapsoVision had a negative trailing twelve-month return on equity of 177.85% and a negative net margin of 214.74%.
Read the conference call transcript
.

CapsoVision (CV) raised $28 million in an IPO on Wednesday, July 2nd 2025. The company issued 5,300,000 shares at a price of $5.00-$5.50 per share. The Benchmark Company and Roth Capital Partners served as the underwriters for the IPO.

Shares of CV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Last Earnings
8/13/2026
Today
11/02/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Healthcare Equipment & Supplies
Sub-Industry
Healthcare Equipment
Current Symbol
NASDAQ:CV
CIK
1378325
Fax
N/A
Employees
99
Year Founded
2005

Price Target and Rating

High Price Target
$10.00
Low Price Target
$9.00
Potential Upside/Downside
+41.2%
Consensus Rating
Hold
Rating Score (0-4)
2.25
Research Coverage
4 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.47)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$25.32 million
Net Margins
-214.74%
Pretax Margin
-214.56%
Return on Equity
-177.85%
Return on Assets
-135.07%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
3.35
Quick Ratio
2.44

Sales & Book Value

Annual Sales
$13.89 million
Price / Sales
24.25
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.28 per share
Price / Book
24.04

Miscellaneous

Outstanding Shares
50,047,000
Free Float
48,896,000
Market Cap
$336.82 million
Optionable
N/A
Beta
-2.45

Social Links

The 7 Best High-Yield Dividend Stocks for 2027 Cover

Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.

Get This Free Report

This page (NASDAQ:CV) was last updated on 11/2/2026 by MarketBeat.com Staff.
From Our Partners